Mark Underwood

4.9k citations

55 papers · 2.8k indexed · 1 hit paper · h-index 25

Impact in

Virology top 0.2%
- HIV Research and Treatment
Infectious Diseases top 0.5%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in

Virology 36
- HIV Research and Treatment 36
Infectious Diseases 38
- HIV/AIDS drug development and treatment 38
- HIV/AIDS Research and Interventions 12

Co-authors: Tamio Fujiwara Karen K. Biron Leroy B. Townsend John C. Drach Brian A. Johns Takahiro Seki Akihiko Sato Howard M. Fried
Journals: Antimicrobial Agents and Chemotherapy (8 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (4 papers)Journal of Virology (4 papers)Antiviral Research (4 papers)Open Forum Infectious Diseases (4 papers)
Partner nations: United States United Kingdom Japan

In The Last Decade

Mark Underwood

52 papers receiving 2.7k citations

Hit Papers

align trajectories log scale

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies 2018 · 243 citations

Peers

Countries citing papers authored by Mark Underwood

Since Specialization

Citations

This map shows the geographic impact of Mark Underwood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Underwood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Underwood more than expected).

Fields of papers citing papers by Mark Underwood

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Underwood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Underwood. The network helps show where Mark Underwood may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark Underwood, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Underwood Line = papers co-authored together Mark Underwood links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Phase 1 Evaluation of VH4524184, a Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile Clinical Infectious Diseases ·Nelly Tagnin Nkuete, Mark Underwood, 一正眞鍋, José Castillo‐Mancilla, Lesley Kahl, Ana Carolina Putini Vieira, Gabriela Ghita, Jerry Jeffrey, Stephen Byrne, L BINET, Joseph Horton, Martin Gartland	2025	0
2	Efficacy and Safety Outcomes in Adults Initiating Dolutegravir/Lamivudine With High Viral Load in the GEMINI-1/-2 and STAT Trials Open Forum Infectious Diseases ·Charlotte-Paige Rolle, José Ramón Arribas, Roberto Ortiz, Mark Underwood, Chris M. Parry, Richard Grove, S. Elenkova, Galibjan Sharipov, 真由美箕曲	2025	0
3	Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies Viruses ·Mark Underwood, Andrian Satrianto, Ruolan Wang, Janet Miller, J Oyee, Brian Wynne, Yasin Taha Al Yasin, Galibjan Sharipov, Choy Man, Jörg Sievers	2024	2
4	Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two‐drug regimen in SWORD‐1/‐2 phase 3 studies British Journal of Clinical Pharmacology ·Rashmi Mehta, Qiaoying Sun, Konstantinos Angelis, 俊郎小田, Lesley Kahl, 宮本勇貴, Jessica Matthews, Brian Wynne, Herta Crauwels, Mark Underwood, Kimberly K. Adkison	2023	2
5	Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks Open Forum Infectious Diseases ·Charlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh, Roberto Ortiz, A. Klimmer, Moti Ramgopal, Dushyantha Jayaweera, Peter A. Leone, Jessica Matthews, Michael Diesburg, Mark Underwood, Konstantinos Angelis, Brian Wynne, Pierre Fortin, Christopher Nguyen, Jean van Wyk, Andrew Zolopa	2023	11
6	Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144 Viruses ·Ruolan Wang, Jonathan Wright, 幹夫小矢野, Mounir Ait‐Khaled, Manojkumar Chopade, Chris M. Parry, Thomas A. Lutz, Daniel Podzamczer, Richard D. Moore, Miguel Górgolas Hernández-Mora, Clifford Kinder, Brian Wynne, Jean van Wyk, Mark Underwood	2023	1
7	75. High Rates of Virologic Suppression with DTG/3TC in Newly Diagnosed Adults with HIV-1 Infection and Baseline Viral Load >500,000 c/mL: 48-Week Subgroup Analysis of the STAT Study Open Forum Infectious Diseases ·Charlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh, Roberto Ortiz, A. Klimmer, Moti Ramgopal, Dushyantha Jayaweera, Peter A. Leone, Jessica Matthews, Michael Diesburg, Mark Underwood, شهریار نیازی, Brian Wynne, Pierre Fortin, Christopher Nguyen, Yunus Akça, Andrew Zolopa	2021	1
8	Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies The Lancet HIV ·Michael Aboud, Chloe Orkin, Daniel Podzamczer, Johannes R. Bogner, David Baker, Marie-Aude Khuong-Josses, Hasna Cahyani Bestari, Konstantinos Angelis, Lesley Kahl, Elizabeth A. Blair, Kimberly K. Adkison, Mark Underwood, Jessica Matthews, Brian Wynne, Kati Vandermeulen, Martin Gartland, Kimberly Y. Smith	2019	77
9	Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial The Lancet Infectious Diseases ·Michael Aboud, Richard Kaplan, Johannes Lombaard, Fujie Zhang, José A. Hidalgo, Giovanny Torres, Marcelo Losso, Ploenchan Chetchotisakd, Carlos Brites, Jörg Sievers, Dannae Brown, Winda Eka Saputri, Mark Underwood, Maria Cláudia Nascimento, Yogesh Punekar, Martin Gartland, Kimberly Y. Smith	2019	104
10	Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance AIDS Research and Human Retroviruses ·James F. Demarest, Mark Underwood, Marty St. Clair, David Dorey, Dannae Brown, Andrew Zolopa	2018	16
11	Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies The Lancet ·Josep M. Llibre, Chien‐Ching Hung, Cynthia Brinson, Francesco Castelli, Pierre‐Marie Girard, Lesley Kahl, Elizabeth A. Blair, شهریار نیازی, Brian Wynne, Kati Vandermeulen, Mark Underwood, Guijun Xian, Martin Gartland, Michael Aboud Hit paper breakdown →	2018	243
12	In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir Journal of Antimicrobial Chemotherapy ·Filippo Canducci, Elisa Rita Ceresola, Diego Saita, Antonella Castagna, Nicola Gianotti, Mark Underwood, Roberto Burioni, Adriano Lazzarin, Massimo Clementi	2013	24
13	Dolutegravir Interactions with HIV-1 Integrase-DNA: Structural Rationale for Drug Resistance and Dissociation Kinetics PLoS ONE ·Felix Deanda, Kendra E. Hightower, Robert T. Nolte, Kazunari Hattori, Tomokazu Yoshinaga, Takashi Kawasuji, Mark Underwood	2013	44
14	Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults AIDS ·Sherene Min, Louis Sloan, Edwin DeJesus, Trevor Hawkins, Lewis McCurdy, Ivy Song, Suresh K. Kwatra, Shuguang Chen, Mark Underwood, Tamio Fujiwara, Stephen C. Piscitelli, Jay Lalezari	2011	171
15	Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes Antimicrobial Agents and Chemotherapy ·Kendra E. Hightower, Ruolan Wang, Felix Deanda, Brian A. Johns, Kurt Weaver, Yujun Zhu, Jon Suzuki, H. Luke Carter, 邓安强, 其谁林, Takahiro Seki, Masanori Kobayashi, Mark Underwood	2011	182
16	Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics Antiviral Research ·Koichiro Nakahara, Chiaki Wakasa-Morimoto, Masanori Kobayashi, Shigeru Miki, Takeshi Noshi, Takahiro Seki, Riley Vercesi Vincent, Joshua M. Seezs, OO Akinnola, Toshio Fujishita, Tomokazu Yoshinaga, Edward P. Garvey, Brian A. Johns, Scott A. Foster, Mark Underwood, Akihiko Sato, Tamio Fujiwara	2008	46
17	Sensitivity of Phenotypic Susceptibility Analyses for Nonthymidine Nucleoside Analogues Conferred by K65R or M184V in Mixtures with Wild-Type HIV-1 The Journal of Infectious Diseases ·Mark Underwood, Lisa Ross, David M. Irlbeck, Peter Gerondelis, E Goldberger, M H St Clair, Lan Trinh, Neil Parkin, E. Randall Lanier	2008	9
18	Differential Impact of Thymidine Analogue Mutations on Emtricitabine and Lamivudine Susceptibility JAIDS Journal of Acquired Immune Deficiency Syndromes ·Lisa Ross, Neil Parkin, Peter Gerondelis, Colombe Chappey, Mark Underwood, M H St Clair, E. Randall Lanier	2006	7
19	Effect of concurrent zidovudine use on the resistance pathway selected by abacavir‐containing regimens HIV Medicine ·危汉桥, Naomi Givens, Christopher Stone, Philip Griffin, Diana M. Gibb, Sarah Walker, Margaret Tisdale, David M. Irlbeck, Mark Underwood, Marty St. Clair, Mounir Ait‐Khaled	2004	30
20	Development of Novel Benzimidazole Riboside Compounds for Treatment of Cytomegalovirus Disease Advances in experimental medicine and biology ·Jeffrey D. Chulay, Karen K. Biron, Kenneth P. Prager, Mark Underwood, Stanley D. Chamberlain, Lloyd Frick, Steven S. Good, M G Davis, Richard J. Harvey, Leroy B. Townsend, John C. Drach, George W. Koszalka	1999	39

About Mark Underwood

Mark Underwood is a scholar working on Virology, Infectious Diseases, Hepatology, Epidemiology and Emergency Medicine, having authored 55 papers that have together received 2.8k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (38 papers), HIV Research and Treatment (36 papers), Biochemical and Molecular Research (13 papers), HIV/AIDS Research and Interventions (12 papers), Cytomegalovirus and herpesvirus research (9 papers), Hepatitis C virus research (7 papers), Herpesvirus Infections and Treatments (6 papers) and Hepatitis B Virus Studies (5 papers). The work is most often cited by research in Virology (1.7k citations), Infectious Diseases (1.9k citations), Epidemiology (871 citations), Emergency Medicine (239 citations) and Parasitology (112 citations). Mark Underwood has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Tamio Fujiwara, Karen K. Biron, Leroy B. Townsend, John C. Drach, Brian A. Johns, Takahiro Seki, Akihiko Sato, Howard M. Fried, Tomokazu Yoshinaga and Clifford I. Voss. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, JAIDS Journal of Acquired Immune Deficiency Syndromes, Journal of Virology, Antiviral Research and Open Forum Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact